(ZTS) Zoetis - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NYSE (USA) | Market Cap: 31.165m USD | Total Return: -53% in 12m
Vaccines, Parasiticides, Animal Diagnostics, Dermatology, Anti-infectives
Total Rating 41
Safety 79
Buy Signal -0.44
Drug Manufacturers - Specialty & Generic
Industry Rotation: -1.3
Industry Rotation: -1.3
Market Cap:
31.2B
Avg Turnover: 492M
Avg Turnover: 492M
Risk 3d forecast
Volatility34.0%
VaR 5th Pctl5.55%
VaR vs Median-0.97%
Reward TTM
Sharpe Ratio-2.08
Rel. Str. IBD1.1
Rel. Str. Peer Group0.6
Character TTM
Beta0.210
Beta Downside0.442
Hurst Exponent0.664
Drawdowns 3y
Max DD61.77%
CAGR/Max DD-0.40
CAGR/Mean DD-1.43
EPS (Earnings per Share)
EPS CAGR: 6.69%
EPS Trend: 82.3%
EPS Trend: 82.3%
Last SUE: -1.50
Qual. Beats: -1
Qual. Beats: -1
Revenue
Rev. CAGR: 2.63%
Rev. Trend: 84.3%
Rev. Trend: 84.3%
Last SUE: -1.16
Qual. Beats: -1
Qual. Beats: -1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Description: ZTS Zoetis
Zoetis Inc. is a global leader in the animal health industry, specializing in the development and commercialization of medicines, vaccines, and diagnostic tools for both companion animals and livestock. Its product portfolio spans parasiticides, dermatology treatments, and precision health solutions, serving a diverse customer base of veterinarians, livestock producers, and pet owners.
The company operates within a specialized pharmaceutical sub-sector characterized by high barriers to entry and long product lifecycles, as animal health products are typically purchased out-of-pocket rather than through third-party payers. Zoetis maintains a diversified revenue stream by balancing high-margin companion animal services with essential livestock productivity solutions. For a deeper look into these fundamental drivers, consider reviewing the detailed metrics on ValueRay.
Headquartered in New Jersey, Zoetis continues to expand its technological footprint through R&D collaborations and advancements in genetic testing and point-of-care diagnostics. This integrated business model allows the firm to capture value across the entire continuum of animal care, from prevention and detection to treatment.
- Companion animal parasiticides and dermatology products drive high-margin revenue growth
- Monoclonal antibody launches for feline and canine osteoarthritis expand total addressable market
- Livestock segment performance fluctuates based on global commodity prices and disease outbreaks
- Direct-to-consumer marketing spend and R&D investment impact short-term operating margins
- Diagnostic platform adoption increases recurring revenue through hardware and consumable sales synergies
Piotroski VR‑10 (Strict)
6.0
| Net Income: 2.64b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA -2.08 > 1.0 |
| NWC/Revenue: 46.49% < 20% (prev 26.84%; Δ 19.66% < -1%) |
| CFO/TA 0.18 > 3% & CFO 2.72b > Net Income 2.64b |
| Net Debt (7.16b) to EBITDA (4.04b): 1.77 < 3 |
| Current Ratio: 3.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (422.4m) vs 12m ago -5.71% < -2% |
| Gross Margin: 70.75% > 18% (prev 0.69%; Δ 7.01k% > 0.5%) |
| Asset Turnover: 65.01% > 50% (prev 65.87%; Δ -0.85% > 0%) |
| Interest Coverage Ratio: 14.74 > 6 (EBITDA TTM 4.04b / Interest Expense TTM 241.0m) |
Altman Z''
7.78
| A: 0.29 (Total Current Assets 6.47b - Total Current Liabilities 2.05b) / Total Assets 15.15b |
| B: 0.94 (Retained Earnings 14.18b / Total Assets 15.15b) |
| C: 0.24 (EBIT TTM 3.55b / Avg Total Assets 14.63b) |
| D: 1.13 (Book Value of Equity 13.42b / Total Liabilities 11.92b) |
| Altman-Z'' Score: 7.78 = AAA |
Beneish M
-2.99
| DSRI: 1.08 (Receivables 1.51b/1.36b, Revenue 9.51b/9.29b) |
| GMI: 0.98 (GM 70.75% / 69.48%) |
| AQI: 0.95 (AQ_t 0.31 / AQ_t-1 0.32) |
| SGI: 1.02 (Revenue 9.51b / 9.29b) |
| TATA: -0.00 (NI 2.64b - CFO 2.72b) / TA 15.15b) |
| Beneish M-Score: -2.99 (Cap -4..+1) = A |
What is the price of ZTS shares?
As of May 17, 2026, the stock is trading at USD 74.22 with a total of 8,942,231 shares traded.
Over the past week, the price has changed by -10.39%, over one month by -38.27%, over three months by -40.63% and over the past year by -52.99%.
Over the past week, the price has changed by -10.39%, over one month by -38.27%, over three months by -40.63% and over the past year by -52.99%.
Is ZTS a buy, sell or hold?
Zoetis has received a consensus analysts rating of 4.26.
Therefore, it is recommended to buy ZTS.
- StrongBuy: 10
- Buy: 4
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ZTS price?
| Analysts Target Price | 130.8 | 76.3% |
Zoetis (ZTS) - Fundamental Data Overview
as of 15 May 2026
P/E Trailing = 12.1869 P/E Forward = 11.8906
P/S = 3.2699
P/B = 10.7407
P/EG = 1.5433
Revenue TTM = 9.51b USD
EBIT TTM = 3.55b USD
EBITDA TTM = 4.04b USD
Long Term Debt = 9.04b USD (from longTermDebt, last quarter)
Short Term Debt = 53.0m USD (from shortTermDebt, last fiscal year)
Debt = 9.10b USD (corrected: LT Debt 9.04b + ST Debt 53.0m)
Net Debt = 7.16b USD (recalculated: Debt 9.10b - CCE 1.94b)
Enterprise Value = 38.32b USD (31.17b + Debt 9.10b - CCE 1.94b)
Interest Coverage Ratio = 14.74 (Ebit TTM 3.55b / Interest Expense TTM 241.0m)
EV/FCF = 17.94x (Enterprise Value 38.32b / FCF TTM 2.14b)
FCF Yield = 5.57% (FCF TTM 2.14b / Enterprise Value 38.32b)
FCF Margin = 22.46% (FCF TTM 2.14b / Revenue TTM 9.51b)
Net Margin = 27.79% (Net Income TTM 2.64b / Revenue TTM 9.51b)
Gross Margin = 70.75% ((Revenue TTM 9.51b - Cost of Revenue TTM 2.78b) / Revenue TTM)
Gross Margin QoQ = 71.66% (prev 68.87%)
Tobins Q-Ratio = 2.53 (Enterprise Value 38.32b / Total Assets 15.15b)
Interest Expense / Debt = 0.68% (Interest Expense 62.0m / Debt 9.10b)
Taxrate = 20.71% (157.0m / 758.0m)
NOPAT = 2.82b (EBIT 3.55b * (1 - 20.71%))
Current Ratio = 3.15 (Total Current Assets 6.47b / Total Current Liabilities 2.05b)
Debt / Equity = 2.81 (Debt 9.10b / totalStockholderEquity, last quarter 3.23b)
Debt / EBITDA = 1.77 (Net Debt 7.16b / EBITDA 4.04b)
Debt / FCF = 3.35 (Net Debt 7.16b / FCF TTM 2.14b)
Total Stockholder Equity = 4.23b (last 4 quarters mean from totalStockholderEquity)
RoA = 18.07% (Net Income 2.64b / Total Assets 15.15b)
RoE = 62.41% (Net Income TTM 2.64b / Total Stockholder Equity 4.23b)
RoCE = 26.76% (EBIT 3.55b / Capital Employed (Equity 4.23b + L.T.Debt 9.04b))
RoIC = 23.15% (NOPAT 2.82b / Invested Capital 12.17b)
WACC = 5.32% (E(31.17b)/V(40.26b) * Re(6.72%) + D(9.10b)/V(40.26b) * Rd(0.68%) * (1-Tc(0.21)))
Discount Rate = 6.72% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: -100.00 | Cagr: -3.73%
[DCF] Terminal Value 88.01% ; FCFF base≈2.19b ; Y1≈2.58b ; Y5≈3.96b
[DCF] Fair Price = 258.1 (EV 115.36b - Net Debt 7.16b = Equity 108.20b / Shares 419.2m; r=6.0% [WACC]; 5y FCF grow 18.89% → 3.0% )
EPS Correlation: 82.30 | EPS CAGR: 6.69% | SUE: -1.50 | # QB: -1
Revenue Correlation: 84.34 | Revenue CAGR: 2.63% | SUE: -1.16 | # QB: -1
EPS current Quarter (2026-06-30): EPS=1.87 | Chg30d=-1.67% | Revisions=-33% | Analysts=11
EPS next Quarter (2026-09-30): EPS=1.85 | Chg30d=+0.53% | Revisions=+17% | Analysts=11
EPS current Year (2026-12-31): EPS=6.90 | Chg30d=-1.83% | Revisions=-71% | GrowthEPS=+7.6% | GrowthRev=+3.6%
EPS next Year (2027-12-31): EPS=7.47 | Chg30d=-1.07% | Revisions=-69% | GrowthEPS=+8.2% | GrowthRev=+4.5%
[Analyst] Revisions Ratio: -71%